No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SGMT Sagimet Biosciences
- 5.080
- +0.290+6.05%
Close May 22 16:00 ET
- 5.130
- +0.050+0.98%
Pre 05:34 ET
162.12MMarket Cap-5805P/E (TTM)
5.200High4.660Low590.34KVolume4.770Open4.790Pre Close2.94MTurnover3.36%Turnover RatioLossP/E (Static)31.91MShares20.71052wk High0.85P/B89.39MFloat Cap2.13052wk Low--Dividend TTM17.60MShs Float20.710Historical High--Div YieldTTM11.27%Amplitude2.130Historical Low4.976Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Stifel cut
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibro
Sagimet Biosciences Is Maintained at Buy by Goldman Sachs
Sagimet Biosciences Is Maintained at Buy by Goldman Sachs
Express News | Goldman Sachs Maintains Buy on Sagimet Biosciences, Lowers Price Target to $23
Express News | HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $32 Price Target
Promising Phase 2b Results Propel Sagimet Biosciences' Denifanstat Towards Pivotal Phase 3 Trial
Comments
$Sagimet Biosciences(SGMT.US$ Sagimet Biosciences Inc - End-of-Phase 2 Meeting With U.S. Food and Drug Administration (FDA) Expected in Q2 of 2024
$Sagimet Biosciences(SGMT.US$
NEWS
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
NEWS
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024
Why Sagimet Biosciences (SGMT) is a Must-Watch Stock: A Deep Dive into Leerink Partners' Latest Coverage.
In the fast-paced world of biotech investments, staying ahead of the curve is crucial for investors seeking substantial returns. Sagimet Biosciences (NASDAQ: SGMT), a company that has recently garnered significant attention from Leerink Partners, an esteemed investment firm, is one such entity that demands your immediate ...
In the fast-paced world of biotech investments, staying ahead of the curve is crucial for investors seeking substantial returns. Sagimet Biosciences (NASDAQ: SGMT), a company that has recently garnered significant attention from Leerink Partners, an esteemed investment firm, is one such entity that demands your immediate ...
$Sagimet Biosciences(SGMT.US$ back to 20
1
$Sagimet Biosciences(SGMT.US$ hurry up and short it already market makers, take your L and move on. so the big boys can buy this out
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg